TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04345432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study.
Study: NCT01914133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given prior to meal the standardized meal
Study: NCT01275638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
Study: NCT03034291

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate
Study: NCT02782715

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
Study: NCT02785757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombin Generation Assay
Study: NCT03929042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture correction girdle
Description: Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
Study: NCT01983865

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to birch pollen
Study: NCT02772380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation following induction of VT/VF
Description: Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
Study: NCT01457339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule(s) for oral use taken once daily for 30 days
Study: NCT03831503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline
Study: NCT00950417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Study: NCT03694522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Administered by intravenous infusion over approximately 30 minutes
Study: NCT03529149

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Urapidil Hydrochloride Injection
Description: Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil Hydrochloride Injection
Description: Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.
Study: NCT03694522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion over approximately 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified FOLFOX6
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Study: NCT02519231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 440mg 1x pid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 440mg 1x pid
Study: NCT00196937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT05176028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
Study: NCT02981459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
Study: NCT03054129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation and balance training
Description: Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Rehabilitation program will be same in this group except balance exercises.
Study: NCT01823588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led reminder through email.
Description: Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.
Study: NCT05249218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase D - Extra 1 Phe exchange from milk or yoghurt
Description: Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase D - Extra 1 Phe exchange from milk or yoghurt
Description: Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase E - Extra 2 Phe exchanges from milk or yoghurt
Description: Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase E - Extra 2 Phe exchanges from milk or yoghurt
Description: Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
Study: NCT02739672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)
Description: Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TWYNSTA(Telmisartan+Amlodipine besylate)
Description: TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
Study: NCT01304823

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactisole
Description: flavoring agent/sweet taste antagonist

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactisole
Description: flavoring agent/sweet taste antagonist
Study: NCT00450749

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05176028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial release
Description: Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
Study: NCT00450749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given PO
Study: NCT01959971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous
Study: NCT00588276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 124I-Iodo-Azomycin Galacto-Pyranoside
Description: You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
Study: NCT03396458

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis B serology
Description: A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
Study: NCT02594878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronatdinatrium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Natrium chloride 9mg/ml
Study: NCT01177488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation Therapeutic Exposure (BATE)
Description: This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapeutic Exposure (BATE)
Description: This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
Study: NCT05291481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPAS-yOUTH
Description: 11-week parent training intervention exclusively delivered to parents
Study: NCT03520387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch nerve radiofrequency ablation (LRFA)
Description: Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulated LRFA with targeted steroid injections
Description: Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AcTIVE-CBT
Description: AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBSCE
Description: TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
Study: NCT00129896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles